In a significant pivot for the Boston-based biotechnology firm, Amylyx Pharmaceuticals announced Tuesday that its experimental drug, avexitide, successfully met the primary endpoint in a pivotal late-stage clinical trial. The study, which evaluated the treatment’s efficacy in managing post-bariatric hypoglycemia (PBH), demonstrated a 55% reduction in serious to severe hypoglycemic events compared to a placebo. This milestone offers a potential lifeline to patients who suffer from life-altering, dangerously low blood sugar levels following weight-loss surgery—a condition for which there is currently no FDA-approved treatment.
For Amylyx, the positive data represents more than just a clinical win; it is a critical step in the company’s efforts to rebuild its reputation and pipeline following the commercial withdrawal of its former flagship ALS treatment, Relyvrio, last year.
The Clinical Challenge: Defining Post-Bariatric Hypoglycemia
Post-bariatric hypoglycemia is a debilitating, often frightening condition that occurs when the body overreacts to food intake after gastric bypass or other bariatric procedures. By the time the sugar reaches the bloodstream, the patient’s insulin production can spike uncontrollably, causing glucose levels to plummet.
The consequences are severe. When the brain is deprived of glucose, patients experience profound cognitive impairment, including confusion, dizziness, slurred speech, and loss of motor coordination. In more extreme cases, these "hypoglycemic events" can lead to fainting, seizures, and even comas. According to research cited by the Cleveland Clinic Journal of Medicine, the condition affects between 10% and 33% of patients who undergo bariatric surgery, creating a significant and unmet medical need.
The Mechanism of Action
Avexitide offers a novel approach to stabilizing these erratic blood sugar levels. Interestingly, it functions by interacting with the same GLP-1 receptors targeted by the current generation of blockbuster weight-loss and diabetes medications, such as those sold by Novo Nordisk and Eli Lilly. However, while those drugs are designed to mimic GLP-1 to aid in weight loss and blood sugar management, avexitide acts as a receptor blocker. By antagonizing these receptors, the drug effectively decreases the pancreas’s overproduction of insulin, providing a "brake" on the system that prevents sugar levels from crashing.
Chronology of a Corporate Pivot
The journey to this week’s announcement has been marked by rapid strategic maneuvering and a willingness to bet on high-potential assets.
- 2023–2024 (The ALS Setback): Amylyx faced a existential crisis when its ALS drug, Relyvrio, failed to demonstrate clinical efficacy in a confirmatory Phase 3 trial. The company made the difficult, rare decision to withdraw the product from the market, leading to significant restructuring and workforce reductions.
- Early 2024 (The Acquisition): Seeking to revitalize its pipeline, Amylyx executed a $35 million acquisition of avexitide during the bankruptcy proceedings of Eiger BioPharmaceuticals. The acquisition was considered a masterstroke of "buy-low, build-high" strategy, as the asset came with existing mid-stage trial data for both PBH and congenital hyperinsulinism.
- Throughout 2024: The company focused its internal resources on refining the regulatory pathway for avexitide, leveraging the drug’s existing "breakthrough therapy" designation from the FDA.
- October 2024 (The Milestone): Amylyx reports that the late-stage trial achieved its primary goal, showing a statistically significant 55% reduction in hypoglycemic events. Following the announcement, the company’s stock rose 14% in after-hours trading, signaling investor confidence in the firm’s new direction.
Supporting Data and Safety Profile
The clinical trial results were not only robust in terms of efficacy but also promising regarding safety. In a field where side effects can often preclude the use of new medicines, the researchers noted that the majority of adverse events were classified as mild or moderate.
The most frequently reported side effects included diarrhea and localized reactions at the injection site, such as redness or bruising. These findings are critical, as patients suffering from PBH often struggle to maintain consistent medication regimens; a manageable safety profile is expected to facilitate higher patient adherence once the drug reaches the commercial market.
Justin Klee, co-CEO of Amylyx, emphasized the clinical significance of these findings. "What we heard very consistently from endocrinologists and people with PBH is that every one of these events is a medical emergency," Klee said in an interview. "Preventing even a single event matters."
Official Responses and Industry Outlook
The leadership team at Amylyx—co-CEOs Justin Klee and Joshua Cohen—has expressed immense optimism regarding the data. Cohen described the results as a "home run" that surpassed the company’s internal projections.
Analyst Projections
Market analysts have responded to the data with enthusiasm. Mizuho Securities recently projected that risk-adjusted revenue for avexitide could climb to $1.3 billion by 2040. Joseph Thome, an analyst at TD Cowen, provided an even higher estimate, modeling peak annual U.S. sales at $1.5 billion. Thome noted that this figure might actually be conservative, assuming that the medical community’s awareness and diagnostic capabilities regarding PBH improve as a treatment becomes available.
The Regulatory Path Forward
Amylyx has confirmed that it intends to submit a formal New Drug Application (NDA) to the FDA before the end of the year. While the co-CEOs declined to confirm whether they would meet with FDA staff prior to the filing, they noted that the "breakthrough therapy" designation already in place should facilitate a more streamlined review process. This designation is specifically reserved by the FDA for treatments that address serious conditions where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy.
Broader Implications: A New Era for Amylyx
The success of the avexitide trial serves as a powerful proof-of-concept for the new Amylyx. By successfully transitioning from a company defined by a single, failed asset to a company with a diversified and promising pipeline, Amylyx is positioning itself as a resilient player in the rare disease space.
Beyond avexitide, the company is continuing to investigate AMX0035 for the treatment of Wolfram syndrome, a rare and progressive neurodegenerative condition. It also holds an experimental genetic medicine program for ALS in its early-stage pipeline.
Financial Runway
Despite a net loss of $43 million in the second quarter of 2024, the company remains on solid financial footing. With $251 million in cash and cash equivalents as of June 30, Amylyx management estimates it has enough runway to sustain operations well into 2028. This stability allows the company to focus on the commercial launch preparations for avexitide while continuing its R&D efforts.
The Path to Commercialization
The road ahead involves navigating the complexities of launching a specialized drug for a condition that has historically been under-diagnosed. Amylyx’s team is currently scaling its commercial infrastructure, preparing for what they hope will be the first-ever approved therapy for a condition that has plagued bariatric patients for decades.
As Amylyx prepares its regulatory submission, the medical community—and investors alike—will be watching closely. If approved, avexitide will not only represent a financial windfall for the company but will also provide a long-awaited clinical solution for a patient population that has, until now, been left with few options beyond dietary modification and the constant, lingering fear of their next hypoglycemic episode.
In the words of the steering committee members who reviewed the trial data: for those suffering from this debilitating condition, the arrival of such a treatment is a cause for relief that is, quite literally, "over the moon."
About the Author
